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Switzerland (6). Failure to complete a
full course of treatment may lead to
relapse and emergence of resistant
strains. A growing proportion of cases
of tuberculosis observed in Europe is
in migrants, some undocumented,
from the developing world (3). Strong
political measures should be enforced
to ensure access to healthcare services
with respect to confidentiality (as
recently stated in the Netherlands) (7).
Much emphasis has been put on
screening at time of arrival. Screening
can be conducted for immigrants and
asylum seekers, but undocumented
migrants are not screened (8).
Facilitated access to medical services
and free affordable therapy is a neces-
sity; active tuberculosis develops in
most foreign-born residents several
years after their arrival (2). In an era of
high mobility, specific innovative pro-
grams should be established to control
and prevent tuberculosis for this high-
risk, foreign-born population. Early
detection with nonidentifying tubercu-
losis tracking systems (9), screening at
unspecialized clinics (10), and free
treatment with adequate administra-
tive measures are needed.
Industrialized countries must take
responsibility to reduce the spread of
resistant tuberculosis. 
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To the Editor: Mycobacterium
chelonae is rapid growing and is ubiq-
uitous in the environment, including
soil, water, domestic and wild ani-
mals, and milk and fruit products. It
can be associated with infections of
the soft tissue, lung, bone, joint, cen-
tral nervous system, and eye. M. che-
lonae infections in an immunocom-
promised host are disseminated in
>50% of those infected; chronic use
of steroids, even in low doses, seems
to be the most important predictive
factor for disseminated disease (1,2).
In immunocompetent hosts, nontuber-
culous mycobacteria can colonize
body surfaces and be secreted for pro-
longed periods without causing dis-
ease. In hematopoietic stem cell and
solid organ transplant recipients,
infections with nontuberculous
mycobacteria are common and may
be a source of illness and death (3).
We describe a case of localized cuta-
neous  M. chelonae infection after a
dog bite in a kidney-pancreas trans-
plant recipient.
A 43-year-old female patient
underwent kidney transplantation for
diabetic nephropathy in 1985. After
loss of organ function due to chronic
rejection, she underwent combined
kidney-pancreas transplantation 5
years later, in 1990. Because of chron-
ic rejection, the patient lost the kidney
graft 5 years later, in 1995, and went
back on dialysis with a well-function-
ing pancreas graft. In 2004, the patient
was bitten on the right forearm by a
dog. She was on immunosuppressive
therapy of prednisolone (5 mg/day),
cyclosporine-A (trough levels of 100
ng/dL), and azathioprine (50 mg/day).
The initial lesion healed without
major complication. After several
days, a single firm edematous plaque
of 3 x 5 cm developed at the site of the
animal bite, and the patient was
admitted to the Department of
Dermatology. Empiric antimicrobial
combination therapy, including clin-
damycin (300 mg every 8 hours) and
ciprofloxacin (500 mg every 12
hours), was initiated. As no clinical
improvement was achieved, a biopsy
was performed, which showed a gran-
ulomatous inflammation with a high
number of mycobacteria (Figure).
Atypical mycobacteria were cultured
from a second biopsy (Löwenstein-
Jensen/Stonebrink, Heidelberg, Ger-
many); M. chelonae was identified by
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polymerase chain reaction. Therefore,
antimicrobial therapy was changed to
clarithromycin (500 mg twice daily)
for 6 months. Although cyclosporine-
A dosage was reduced with initiation
of antimicrobial therapy, trough level
increased to 350 ng/mL; therefore,
further dose reduction was performed.
Within a few weeks, the lesion disap-
peared completely, and the patient
retained good pancreatic graft func-
tion. To rule out dissemination to
other organs, a computed tomography
of head, thorax, and abdomen was
performed at time of diagnosis.
In the immunocompromised host,
an uncontrolled proliferation of pri-
marily colonizing or contaminating
pathogens or commensals can
progress to severe disease. Diagnosis
is often difficult because patients with
these infections may have atypical
symptoms due to immunosuppressive
therapy. If diagnosis is made early,
dissemination can likely be avoided.
Therefore, suspicious cutaneous
lesions should be biopsied for
histopathologic examination, and spe-
cial stains and tissue cultures should
be performed for detecting fungi,
viruses, and bacteria, including
mycobacteria (3,4). Nontuberculous
mycobacteria are resistant to conven-
tional tuberculostatic therapy and
have variable susceptibility to other
antimicrobial agents (1,2,5). Clari-
thromycin seems to be the most active
drug, and azithromycin might also
have good activity (3–6). Clari-
thromycin has been administered suc-
cessfully as monotherapy, and our
case confirms these data. However,
several cases of resistance have been
described, and use of at least 1 other
drug, such as an aminoglycoside or a
quinolone, in addition to clar-
ithromycin has been recommended
(1,4,7–9). Clarithromycin is a potent
inhibitor of cytochrome P450 (3,4).
Therefore, cyclosporine-A and tacro-
limus levels have to be monitored
exactly, and dose adjustments may be
required. Duration of therapy depends
on the isolate, site of infection, and
clinical response to therapy, but in
general, it should be continued for at
least 6 months (3,8). 
Thus far only a few cases of infec-
tions with M. chelonae in kidney,
heart, liver, and lung transplant recip-
ients have been described (3). Most of
these infections were disseminated
and often resulted in chronic infec-
tion. To our knowledge, this report is
the first of localized cutaneous
disease from M. chelonae, which
completely healed within 3 months, in
a kidney-pancreas transplant recipi-
ent. Although M. chelonae might be
part of the colonizing oral flora of
dogs, it is more likely that the bite
contributed to translocation of the
transient dermal flora. Any factor that
disrupts the skin barrier, such as
insulin self-injection in diabetes
patients, surgical wound, insect sting,
or animal bite, might be associated
with this type of infection (10,11). We
conclude that early diagnosis prevents
dissemination, leads to rapid clinical
response, and allows antimicrobial
monotherapy with a macrolide. Such
an approach preserved the function of
the pancreatic allograft.
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Figure. Skin biopsy of the lesion showed granulomatous infection with Mycobacterium
chelonae (Ziehl-Neelsen stain, x40)